Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.